LAM-003 overcomes mutations that confer FLT3i resistance. (A) Ba/F3 cells harboring WT FLT or indicated FLT3 mutants were treated with increasing concentrations of LAM-003 for 24 hours before flow cytometry was performed to assess FLT3 expression. (B) Ba/F3 cells expressing FLT3-ITD or FLT3-ITD F691L were treated with crenolanib or LAM-003 for 72 hours. (C) Parental MOLM-13 cells (solid lines) or MOLM13-RES cells (hatched lines) were treated with tandutinib, sorafenib, or LAM-003 at the indicated concentrations for 72 hours before viability was assayed by using CellTiter-Glo. Data in all panels represent the mean ± SD from at least 2 independent experiments, each performed in duplicate.